FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ProQuest Investments IV, L.P. 		2. Issuer Name and Ticker or Trading Symbol

EAGLE PHARMACEUTICALS, INC. [ EGRX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

, 2430 VANDERBILT BEACH ROAD, #108 - 190 		3. Date of Earliest Transaction (MM/DD/YYYY)

9/30/2016
(Street)

NAPLES, FL 34109
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock $0.001 par value   9/30/2016     S    22100   D $70.06   (2) 4373987   I   By ProQuest Investments IV, L.P.   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities.
( 2)  Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $70.00 to $70.38. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ProQuest Investments IV, L.P.
2430 VANDERBILT BEACH ROAD, #108 - 190
NAPLES, FL 34109
X

ProQuest Financial LLC
2430 VANDERBILT BEACH ROAD, #108-190
NAPLES, FL 34109
X

ProQuest Associates IV LLC
2430 VANDERBILT BEACH ROAD, #108 - 190
NAPLES, FL 34109
X

Moorin Jay
C/O PROQUEST INVESTMENTS
2430 VANDERBILT BEACH ROAD, #108 - 190
NAPLES, FL 34109
X

SCHREIBER ALAIN
C/O PROQUEST INVESTMENTS
2430 VANDERBILT BEACH ROAD, #108 - 190
NAPLES, FL 34109
X


Signatures
/s/ Pasquale DeAngelis 10/4/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Eagle Pharmaceuticals Charts.
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Eagle Pharmaceuticals Charts.